Abstract:The results of recent studies suggest that a relative hypogonadism in men is associated with several established risk factors for prevalent diseases. Therefore, we determined total and free testosterone, luteinizing hormone (LH), and sex-hormone binding globulin (SHBG) in a cohort of randomly selected men (n = 659) at 67 years of age. These data were analyzed cross-sectionally in relation to blood glucose and serum insulin, which were measured while fasting and after an oral glucose tolerance test, in addition… Show more
“…Diabetes was identified primarily by self-report [45–48] with confirmation by additional testing or record review [45], or by FPG levels and medication use [49–52]; several studies used 2-hour glucose levels as well [53–57]. It is possible that this variety in definitions contributed to inconsistent associations.…”
Section: Resultsmentioning
confidence: 99%
“…Five studies found an association between lower total T and incident diabetes [49, 55, 47, 58, 57], while 3 studies reported no association [46, 59, 48]. Two studies found an association between lower bioavailable or free T and incident diabetes [49, 57], while 3 studies reported no association [51, 46, 59]. One study examined total E2 and found an association [48], while another examined total and bioavailable E2 in men and diabetes and found no association [55].…”
Section: Resultsmentioning
confidence: 99%
“…One study examined total E2 and found an association [48], while another examined total and bioavailable E2 in men and diabetes and found no association [55]. Five studies examining SHBG found an association between lower SHBG and incident diabetes [49, 51, 46, 58, 57]; 4 did not [53, 56, 59, 48], particularly after adjustment for waist measures. Tibblin et al [57] examined IGT as well as diabetes as an outcome and also reported that lower total T was associated with incident IGT.…”
Endogenous sex hormones predict impairments of glucose regulation. Cross-sectional studies suggest that lower levels of testosterone in men and higher levels in women increase risk of metabolic syndrome and diabetes, while lower levels of sex hormone binding globulin in both men and women increase risk of metabolic syndrome and diabetes. In a systematic review, we summarize existing longitudinal studies, which suggest similar patterns. However, these studies are often limited to a single sex steroid measure. Whether these associations are primarily a marker of adiposity, and whether these associations differ between younger eugonadal vs. older hypogonadal adults is also uncertain. The impact of exogenous sex steroid therapy may not reflect relationships between sex hormones and impaired glucose regulation that occur without supplementation. Therefore, examination of endogenous sex steroid trajectories and obesity trajectories within individuals might aid our understanding of how sex steroids contribute to glucose regulation.
“…Diabetes was identified primarily by self-report [45–48] with confirmation by additional testing or record review [45], or by FPG levels and medication use [49–52]; several studies used 2-hour glucose levels as well [53–57]. It is possible that this variety in definitions contributed to inconsistent associations.…”
Section: Resultsmentioning
confidence: 99%
“…Five studies found an association between lower total T and incident diabetes [49, 55, 47, 58, 57], while 3 studies reported no association [46, 59, 48]. Two studies found an association between lower bioavailable or free T and incident diabetes [49, 57], while 3 studies reported no association [51, 46, 59]. One study examined total E2 and found an association [48], while another examined total and bioavailable E2 in men and diabetes and found no association [55].…”
Section: Resultsmentioning
confidence: 99%
“…One study examined total E2 and found an association [48], while another examined total and bioavailable E2 in men and diabetes and found no association [55]. Five studies examining SHBG found an association between lower SHBG and incident diabetes [49, 51, 46, 58, 57]; 4 did not [53, 56, 59, 48], particularly after adjustment for waist measures. Tibblin et al [57] examined IGT as well as diabetes as an outcome and also reported that lower total T was associated with incident IGT.…”
Endogenous sex hormones predict impairments of glucose regulation. Cross-sectional studies suggest that lower levels of testosterone in men and higher levels in women increase risk of metabolic syndrome and diabetes, while lower levels of sex hormone binding globulin in both men and women increase risk of metabolic syndrome and diabetes. In a systematic review, we summarize existing longitudinal studies, which suggest similar patterns. However, these studies are often limited to a single sex steroid measure. Whether these associations are primarily a marker of adiposity, and whether these associations differ between younger eugonadal vs. older hypogonadal adults is also uncertain. The impact of exogenous sex steroid therapy may not reflect relationships between sex hormones and impaired glucose regulation that occur without supplementation. Therefore, examination of endogenous sex steroid trajectories and obesity trajectories within individuals might aid our understanding of how sex steroids contribute to glucose regulation.
“…The study comprised two cohorts of men from Go Èteborg; both cohorts were population-based and in both the men were personally invited to participate. The cohort of men born in 1913 were randomly selected from the general population and has been extensively described elsewhere [13]. Altogether, 973 men were initially invited to a health screening examination in 1963, of whom 855 (88%) participated.…”
Objective To assess the risk of over-diagnosing and overtreating prostate cancer if population-based screening with serum prostate-speci®c antigen (PSA) is instituted. Patients and methods From a serum bank stored in 1980, PSA was analysed in 658 men with no previously known prostate cancer from a well-de®ned cohort from Go Èteborg, Sweden (men born in 1913); the incidence of clinical prostate cancer was registered until 1995. From the same area, and with the same selection criteria, another cohort of 710 men born in 1930±31, who in 1995 accepted an invitation for PSA screening, was also analysed. Results Of men born in 1913, 18 (2.7%) had died from prostate cancer and the cumulative probability of being diagnosed with clinical prostate cancer was 11.1% (5.0% in those with a PSA level of <3 ng/mL vs 32.9% in those with a PSA level of >3 ng/mL, P<0.01). The mean lead-time from increased PSA (>3 ng/mL) to clinical diagnosis was 7 years. The prostate cancer detection rate in men born in 1930±31 was 4.4% (22% among those with increased PSA levels) and 30 of 31 detected cancers were clinically localized. Conclusions Screening and sextant biopsies resulted in a lower detection rate (22%) than the cumulative risk of having clinical prostate cancer (33%) in men with increased PSA levels, indicating that under-diagnosis rather than over-diagnosis is the case at least with one-time' screening. Even if the stage distribution in screening-detected cancers seems promising (and thus may result in reduced mortality) it is notable that screening 67-year-old men will result in treatment a mean of 7 years before clinical symptoms occur and only one in four men anticipated to develop prostate cancer will die from the disease within 15 years. Large randomized screening trials seem mandatory to further explore the bene®ts and hazards of PSA screening.
“…Low testosterone levels are associated with abdominal obesity and insulin resistance in men,39 and are an independent risk factor for developing T2D 40. Insulin sensitivity, visceral fat mass, blood pressure, and plasma lipids improve with testosterone substitution 41,42.…”
Section: Sex Differences In Hormonal Pathophysiologymentioning
BackgroundWomen with type 2 diabetes (T2D) are less likely to reach the goals for hemoglobin A1c compared with men, and have higher all-cause mortality. The risk of cardiovascular disease is elevated among both men and women with T2D, however, the risk has declined among men over recent years while it remains stationary in women. Reasons for these sex differences remain unclear, and guidelines for diabetes treatment do not differentiate between sexes. Possible causes for varying outcome include differences in physiology, treatment response, and psychological factors. This review briefly outlines sex differences in hormonal pathophysiology, and thereafter summarizes the literature to date on sex differences in disease course and outcome.MethodsSystematic searches were performed on PubMed using “sex”, “gender”, and various glucose-lowering therapies as keywords. Earlier reviews are summarized and results from individual studies are reported. Reference lists from studies were used to augment the search.ResultsThere is an increased risk of missing the diagnosis of T2D when screening women with only fasting plasma glucose instead of with an oral glucose tolerance test. The impact of various risk factors for complications may differ by sex. Efficacy and side effects of some glucose-lowering drugs differ between men and women. Men with T2D appear to suffer more microvascular complications, while women have higher morbidity and mortality in cardiovascular disease and also fare worse psychologically.ConclusionFew studies to date have focused on sex differences in T2D. Several questions demand further study, such as whether risk factors and treatment guidelines should be sex-specific. There is a need for clinical trials designed specifically to evaluate sex differences in efficacy and outcome of the available treatments.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.